Evenativ

Evenativ is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare and serious diseases. Originally founded as a joint venture between Takeda Pharmaceutical Company Limited and Shire plc, Evenativ was established in 2017 to accelerate the growth of Shire’s specialty pharmaceutical business. Following Shire’s acquisition by Takeda in 2019, Evenativ became a fully owned subsidiary of Takeda, continuing to operate independently under its own brand.

The company specializes in treating rare diseases, particularly in the areas of hematology, rare diseases, and rare endocrine disorders. Its portfolio includes several approved therapies, such as **Elaprase** (idursulfase) for Mucopolysaccharidosis Type II (Hunter syndrome), **Vimizim** (elosulfase alfa) for Mucopolysaccharidosis Type IVA (Morquio A syndrome), and **Kuvan** (sapropterin dihydrochloride) for phenylketonuria (PKU). Evenativ also engages in research and development to expand its pipeline of potential treatments for underserved patient populations.

Headquartered in Cambridge, Massachusetts, Evenativ operates globally with a focus on improving patient access to specialized therapies. The company collaborates with healthcare providers, patient advocacy groups, and regulatory agencies to enhance treatment options and support those affected by rare diseases. Its mission aligns with Takeda’s broader commitment to advancing medical science and delivering meaningful impact in rare disease management.

Evenativ emphasizes patient-centric approaches, including education, support programs, and initiatives to raise awareness about rare conditions. By leveraging Takeda’s resources and expertise, the company aims to drive innovation while maintaining a strong focus on ethical business practices and sustainable growth.